Where To Invest Now
June 19, 2017
Market Strategies Newsletter Sample Issue
Where To Invest Newsletter
Balanced Investing Strategies To Make Money In Up Or Down Markets
A Publication of Princeton Research, Inc. (www.PrincetonResearch.com)
Contributing Staff: Michael King, Charles Moskowitz
Read the June 19, 2017 – Where To Invest Now Newsletter in .pdf format HERE
Read the June 12, 2017 – Where To Invest Now Newsletter in .pdf foramt HERE
Proven Trading Success
Our Recent WINNING TRADES
177% Gains on SPY Calls in 1 Day
55% Gains on SPY Calls in 2 Days
485% Gains on SIG Calls in 10 Days
134% Gains on SIG Calls in 7 Days
91% Gains on SPY Calls in 6 Days
100% Gains on SPY Calls in 2 Days
112% Gains on SLM Calls in 31 Days
226% Gains on SPY Calls in 2 Days
125% Gains on SPY Calls in 2 Days
100% Gains on SPY Puts in 1 Day
57% Gains on JBLU Calls in 8 Days
18% Gains on SPY Calls in 1 Day
91% Gains on SPY Calls in 1 Day
63% Gains on SPY Calls in 2 Days
100% Gains on SPY Calls in 1 Day
175% Gains on SPY Puts in 3 Days
57% Gains on JBLU Calls in 8 Days
See all trades in past newsletter issues.
Remember, these trades are based on your participation in the
TEXTING SERVICE TO RECEIVE ALL UPDATES.
New Trades Will Be TEXTED To MEMBERS
For Free Where To Invest Your Money Now
High Return Investments Trade Alerts
Go To: PrincetonResearch.com/alerts.htm
SPECIAL RATES Available for VIP MEMBERSHIP
Get the lowest full membership rates available.
NOTE: This is a Sample Issue Only!
TO GET OUR TRADE ALERTS BY TEXT MESSAGE AND
THE COMPLETE VIP MEMBERS ONLY MARKET STRATEGIES NEWSLETTER ISSUES
Visit: PrincetonResearch.com/join.htm
Follow Our Marketed Weathered,
Time Tested Trading Rules That
PROTECT YOUR CAPITAL And SECURE PROFITS
Now you can profit from investing trade alerts from our traders with over 75 combined years of successful investing experience.
- Make Money In Up Or Down Markets — Our trading alerts balanced investing strategies are designed and proven to make money in up or down markets.
- Done For You – All the stock options picking, research and trading analysis is done for subscribers. This is not a ‘class’ or a ‘training course’… this is us doing ALL the work… from research to sending you a text on what to trade, along with recommended amounts…
- SAFETY – We strictly follow our Tested, Market Weathered Trading Rules that are proven time and time again to protect our (and now your) investment capital from losses while effectively allowing us to Keep The Profits We Make.
So even though we trade options to get the profits you see above — We can do it with minimal risk and Maximum Profit Potential.
You Don’t Need To Learn Any Trading Skills Or
Do Any Time Consuming Analysis and Tracking
+++ We DO IT ALL FOR YOU! +++
We tell you where, when and how much to trade and you get to sit back and enjoy the rewards!
The specific buy and sell trading alerts are sent directly to you by e-mail and text message. So you can get in on and cash out on our winning trades fast and at the right time.
Get Started with Any Amount – Follow our recommended trading guidelines for a $10,000 portfolio or invest more or invest less — Whatever you are comfortable with. Your investment is protected because Time Tested Trading Rules PROTECT YOUR CAPITAL And KEEP YOUR PROFITS.
Join Us Today.
Lock in the Lowest Membership Rates Available HERE
2 FOR 1 BONUS:
Your Membership includes access to both:
Trade Alerts by Text Message and e-mail
AND
The Market Investing Strategies Newsletter
Full Members Only Edition
Our Where To Invest Now For Profits In Up or Down Markets Newsletter is more compact, informative, effective and quicker to read then the major, big name publications. AND there are NO ADS to wade through.
The Members Edition Newsletter is sent to you by e-mail Monday Mornings and available in the Members Area along with our archive of past issues.
SPECIAL RATES Available for VIP MEMBERSHIP
Get the lowest full membership rates available.
A Sample of the Where To Invest Now Newsletter
Information Our Members Get Follows
Investing Trade Alerts
Charles Moskowitz Discussion
2017 YTD Profits $ 7916
Over 79% Returns
Open Positions:
Long 6 TJX July 75 Calls
Funds in Use $ 510
I watched the Sunday morning shows today and was VERY surprised with the comments of even the most liberal of Democrats to the way things are progressing in the “________-GATE” (you fill in the appropriate issue(s) that with all the bluster and leaking going on there still has not emerged even the scintilla of an actual piece of evidence. Imagine my surprise when David Brooks said (on Meet the Press) that “for all of the smoke there seems to be no fire.” You don’t get more liberal than the Op/Ed page editor of the NY Times. It made me want to go online and re-up my subscription!!
I also noticed that last night (Saturday) that MSNBC is airing a multipart special on Watergate. I recorded it and was surprised that they didn’t just use the “real” people involved, but also had Redford and Hoffman on for their comments. I like to see both of them on TV or at the movies, but really, The Electric Horseman and Tootsie discussing the issues alongside Ben Bradley, Woodward and Bernstein?
I took the time to put out a “Special Note” on Friday about the Amazon-Whole Foods deal. I can’t stress enough the significance of this deal. So what if AMZN can’t make money at this point in the Grocery business. It has the cash flow for it not to be a problem and the action in anyone in that business on Friday whether only a partial participant (WMT,TGT or COST) or the others like KR, SFM, or UNFI tells you all you have to know about how they feel about this “category killer” coming to town. While the argument about declining commodity prices and the deflation in pricing on the shelves gives these companies angina, this is just part of a cycle. It will reverse at some point and go the other way. That’s what cycles do. And I can’t imagine with its massive cash flow AMZN is the least bit concerned about short term profits. So, get ready for Prime members to get free and speedy delivery of any order over $50. As everyone who shops knows, that’s just one or two bags. Then try to imagine what will happen once fully entrenched in the business when AMZN raises prices even a nickel on some items.
As to the market and its action, I will make the point that I’ve used to evaluate short term trading before: For all of its up and down price action, we are doing something that we have done on each breakout for quite some time now…we are consolidating OVER our points of breakout. While we may have some violent action to the downside on political or geopolitical surprises, unless we get a close under 2380, the “buy the dips” seems to carry the day…CAM
Investing Trade Alerts Summary
$10,000 Trading Account Trade Table
DATE |
TRADES |
PRICE |
COST |
PROCEEDS |
RESULTS |
06/16 |
Sold 6 AMBA July 55 Calls |
0.60 |
360 |
330 Loss |
|
06/15 |
Sold 10 SPY June 244 Calls |
0.21 |
210 |
210 Loss |
|
06/14 |
Sold 10 HL July 6 Calls ( 50 % loss rule) |
0.12 |
120 |
110 Loss |
|
06/14 |
Bought 10 SPY June 244 Calls |
0.42 |
420 |
||
06/14 |
Bought 6 TJX July 75 Calls |
0.85 |
510 |
||
06/12 |
Bought 6 AMBA July 55 Calls |
1.15 |
690 |
||
06/05 |
Bought 10 HL July 6 Calls |
0.23 |
230 |
DATE |
TRADES |
PRICE |
COST |
PROCEEDS |
RESULTS |
06/09 |
Bought 10 SPY June9th 243.50 Calls andsold the same day @ 0.06 for small loss |
0.07 |
70 |
60 |
10 Loss |
06/09 |
Bought 10 SPY June 9th 243 Calls andsold them Same day @ 4 0.50 |
0.18 |
180 |
500 |
320 Gain |
06/09 |
Sold 10 SPY June9th 244 Calls @ $ 0.30 ( 50% Loss Rule ) |
1.09 |
300 |
310 Loss |
|
06/07 |
Bought 6 BBRY June 11.50 Calls |
0.22 |
132 |
||
06/07 |
Sold Short 10 SPY June 9th 244.50 Calls expired worthless on June 9th |
0.34 |
340 |
340 Gain |
|
06/09 |
Sold 2 SIG June 55 Calls |
3.75 |
750 |
622 Gain |
|
06/07 |
Sold 2 SIG June 55 Calls( 100% Profit Rule + Gap ) |
1.50 |
300 |
172 Gain |
|
06/06 |
Bought 6 TBT July 36Calls and Sold them on June 9th @ $ 1.09 |
0.84 |
504 |
654 |
150 Gain |
06/06 |
Bought 10 SPY June9th 244 Calls |
0.61 |
610 |
||
06/05 |
Bought 10 HL July 6 Calls |
0.23 |
230 |
||
06/05 |
Sold 2 SJM June 130 Calls |
2.99 |
598 |
278 Gain |
|
06/05 |
Sold 5 SPY June9th 243.50 Calls |
1.19 |
595 |
285 Gain |
|
06/05 |
Sold 6 SMG June 90 Calls |
0.20 |
120 |
165 Loss |
|
06/02 |
Sold 5 SPY June9th 243.50 Calls |
1.24 |
620 |
310 Gain |
|
06/02 |
Sold 2 SJM June $130 Calls 100% Profit Rule |
3.50 |
700 |
360 Gain |
|
06/01 |
Bought 5 SPY June9th 243.50 Calls |
0.62 |
310 |
||
06/01 |
Bought 4 SIG June $55 Calls |
0.64 |
256 |
||
06/01 |
Bought 10 SPY June 9th 243.50 Calls |
0.62 |
620 |
||
05/30 |
Bought 1 SMG June9th 243.50 Calls |
0.60 |
60 |
||
05/30 |
Bought 5 SMG June 90 Calls |
0.45 |
225 |
||
05/01 |
Bought 2 SJM June $ 130 Calls |
1.60 |
320 |
3rd Week expiration when the month is listed without a date
Previous closed out trades not listed here may be seen in previous market letters in the
VIP Subscribers Members Area.
Remember, these trades are based on your participation in the
Subscriber Members Only
TEXTING SERVICE TO RECEIVE ALL UPDATES.
NOTE: In texting we have a limited amount of words. In the interest of brevity:
The Quantity and Strike Price for each trade is specific. 1=January, 2=February
Trading is hypothetical. We may trade weekly options and they are noted: SPY 1/25 147 for
SPY Jan 25th 147 Calls or Puts.
New Trades Will Be TEXTED To MEMBERS
Market Strategies Technical Information
SUPPORT RESISTANCE
S&P 500 2411 2470
NASDAQ (QQQ) 130.40 142.10
Trans 9160 9525
DOW 21,075 21,520
TLT 123.20 131.20
Where To Invest Now
Fundamental Analysis Stocks To Buy with Stops
Using fundamentals the following are stocks to trade hypothetically. They have done well. We have taken numerous profits as indicated on the table below. In addition many have been stopped out with small losses. All indicated on the table below, balance is critical.
Alibaba has made a few points. We are raising the stop loss price.
Semiconductors are a leader on NASAQ. We remain long SIMO.
We have no position in Alcoa AA. If long use the 50 day price m.a. as ($ 32.80) a risk point.
Flushing Financial FFIC fell to and held the 50 day price moving average on March 3rd, which was a buying opportunity. We would buy the Flushing Financial.
Boeing is on its way to $ 200.
We are not involved with Bristol Myers.
Hecla Mining is a buy as long as it is above the 13 day price moving average.
We took profits on ENZ and want to buy at lower prices.
The HDGE is not yet relevant at this time. It is a decent long as long as it can trade above its 13 day price moving average.
| Symbol | Name | Business Description | PE | P/S | MV
million |
Price | Buy or Sell Limit | Stop Loss
Or offset |
| BABA | Alibaba | China; more of a retailer than Amazon | 50.67 | 13.21 | 275.5B | 139.80 | Bought @ $ 111 on 4/7/17 opening | Raising stop loss to $129x |
| AMZN | Amazon | Catalog & Mail Order | 189 | 2.90 | 394B | 1006.73 Long | Stopped out $ 976 | $ 976x |
| SIMO | Silicon Motion | Semiconductor solutions for mobile storage and communications | 9.7 | 2.5 | 1.39B | 53.77 | Bought
39.10 01/28/17 |
49.40x |
| CIO | City Office
REIT |
Real Estate Investment Trust high quality Offices | 292 | 5.8 | 396Mln | 12.58 | Re Bought at 12.12 | 11.50x |
| TPC | Tutor Perini | Construction | 12 | 0.25 | 1.3B | 27.10
Stopped out28.90 05/04 |
19.40
10/31/16 |
Looking for place to re-buy |
| SAVE | Spirit Airlines | Discount Airline | 13 | 1.6 | 3.6B | 54.70 | 48.10 | Buy on a dip to $ 52 or close above $54.40 |
| BMY | Bristol Myers | Biopharmaceutical Products | 28 | 5.1 | 94.9B | 53.75
No position
|
Sold at 52.80x
|
Has no direction |
| BA | Boeing | Aerospace, commercial jetliners, military systems | 14 | 0.85 | 81B | 189.80 | Long at
132 10/04/16 |
New stop loss at $ 179 |
| HL | Hecla Mining | Basic Materials | 44 | 3.61 | 1.7B | 5.83
Look for re-entry |
Long at 5.30
5/5/17
|
A good long |
| FFIC | Flushing Financial | Bank Holding company Savings and loans | 13 | 3,5 | 592Mln | 29.45 | 19.10
06/27 |
50 day m.a. at 27.45 |
| AA | Alcoa | Aluminum Processing and Technology | N/A | 0.4 | 9.5B | 32.95
|
21.15 originally bought 2/8/16 | $ 32.10 – 32.75 support |
| ENZ | Enzo Biochem | Life Sciences | NA | 1.35 | 134M | 10.35 | Bought
at 5.13 10/7/16 Looking to re-buy |
Sold on Opening Monday 4/3/17
Sold 8.43 |
| BAC | Bank of America | Commercial Bank | 10 | 2.02 | 165.3B | 23.51
|
Bought at 15.42
9/30/16 |
23.60x stopped out on 3/21/17 |
| HDGE | Advisor Shares | Ranger Bear ETF | 8.69
|
Stopped out on 5/24 | Must close above 8.83 to be long |
Where to Invest Now
Market Strategies $100,000 Trading Account
There were three closed out options positions for a loss of $1,300
and one stock position for a gain of $ 716 last week.
The net was a net weekly loss of $ 584.
Gains the previous week were $ 3,364.
The total gain for the last two weeks is $ 2,780.
The options expire on the third Friday of each Month unless otherwise posted.
The Stock table has the following 20 positions:
AGQ, AMBA, BBRY, EYES ( 2 ), GLYC, GSAT, HL( 2 ) , MOS ( 2 ), OILU, NUGT, REPR, RWM, SAN, SLV, SPXU,TEXQY, TWTR
The options call for a $ 2,500 investment unless otherwise stated; each stock position requires $5,000 unless otherwise mentioned specifically.
Money management is based on a hypothetical $ 100,000.
The 20 stock positions would cost $ 82,064.
The long option position; 12 TJX July 75 Calls would require $ 1020.
The trading is hypothetical and we do not count commission costs.
Executions that have occurred at or near the open or close of trading sometimes vary from our actual numbers. For example, when something opens down and it is through our price, we take the next trade whether it is an uptick or continues lower. This sometimes results in a 50% trade that is slightly above or below the exact number.
Undervalued Small Cap Stocks
Lower priced stocks that look to be a buy:
Lower Capitalized Companies with Great Potential
RMS Medical Products (REPR: $ 0.45) “RMS” or the “Company” is pleased to announce that the umbrella organization of the public health insurance in Germany approved the FREEDOM60® Infusion System for reimbursement. The FREEDOM60® System was registered January, 31st 2017 and listed in the Medical Device Registry in the category mechanical infusion pumps. It is the ONLY device of its kind registered within Germany.
In partnership with Contra Care GmbH, a leader in Germany for Contract Management (reimbursement services) and managed Care, the RMS FREEDOM60®, Freedom Edge®, RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo Subcutaneous Safety Needle Sets™ are now poised to dominate this growing market in Europe.
The United States Food and Drug Administration (“FDA”) renewed the Company’s Certificate to Foreign Government (“CFG”). A CFG is issued for legally marketed devices in the U.S. that are in compliance with the requirements of the Federal Food, Drug, and Cosmetic Act (“FFDCA”). A CFG is required by many market regulators in Asia, Europe, the Middle East and Latin America in order to legally sell medical devices in their territories. The renewal of this CFG confirms RMS devices have been cleared for sale in the U.S. and are in compliance with the requirements of the FFDCA. The CFG can be presented to regulators in foreign markets as part of the medical device registration process. Foreign governments often seek official assurance that products exported to their countries can be marketed in the U.S. and meet specific U.S. regulations, for example, current Good Manufacturing Practice (“cGMP”) regulations and Quality System Regulations (“QSR”).
Torsten Kühn, Chief Executive Officer of Contra Care, commented “as a premium service provider in Germany’s health care system, we aim to partner with leading suppliers to provide the best drugs, medical devices and services to our patients while keeping an eye on the cost efficiency of the treatments we provide. The RMS FREEDOM60® system with its durable and reliable syringe driver and high-quality HIgH-Flo™ subcutaneous safety needle sets are exactly the products we needed for immunoglobulin, antibiotic and many other therapies we are providing today. We are glad that the umbrella organization of Germany’s public health insurance confirms the unmet need by approving the RMS FREEDOM60® System for reimbursement.”
Eric Bauer, Chief Operating Officer of RMS commented, “It can take 12 to 14 months to obtain country registration; by partnering with a leading health care provider, that time was cut significantly. Contra Care is an exceptional partner and we could not be more pleased with our relationship. Germany is going to be a great market for our high quality products and our ever expanding product line. RMS continues to be the Global industry leader and create exceptional partnerships around the world to improve patient quality of life.”
RMS Medical Products is the leading manufacturer of medical products used for home infusions and suctioning. The Infusion product portfolio currently includes the FREEDOM60® and our latest Freedom Edge® Syringe Infusion Drivers, RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in professional healthcare settings as well as at home. The Company’s RES-Q-VAC® line of medical suctioning products is used by emergency medical service providers in addition to a variety of other healthcare providers. The Company’s website may be visited at www.rmsmedicalproducts.com.
Contra Care GmbH, based in Nuremberg, Germany, is specialized in providing Contract Management (reimbursement) Services and managed Care (homecare) solutions for patients with chronic diseases. The company is certificated in accordance with ISO 9001, ISO 27001, ISO 13485 and licensed as a homecare provider of medical devices and treatment services according to German Social Law (SGB).
Enzo Bio-chem (ENZ: $ 10.38)
Enzo Bio-chem closed the calendar year 2016 at $6.94 a share. For the year it was up 54.22% versus the Dow Jones +13%. The relative strength index was 53.41 which is neutral and short interest declined to 827,800 shares. Enzo’s balance sheet closed their first quarter October 31 with $67 million in cash and current equivalents and complete elimination of debt. Both the Clinical Lab and Life Science divisions ended the year profitably. New products were added to their catalog and litigations have moved ahead leaving them as a plaintiff with 6 lawsuits in the Delaware Court and one in the Manhattan Court.
What do I look for in 2017? The market will be interesting in the first half with the Government transition to a new administration. Abbots Summary Judgement request was denied by the Court but the trial date has yet to be set. At some point the 2nd Court of Appeals will rule on Enzo’s appeal on the CT. Courts reversal of the Jury’s decision in the Enzo vs. Apalera Case. The market is giving no value, win or lose, to this decision. The stake is $65 million with no adverse effect if ruled against Enzo. Enzo should again outperform the Dow and S&P in 2017.
Updates on Delaware Litigation
The last earnings report showed a cash position in excess of $65 million with no debt to speak of and a positive cash flow from their operating divisions. The only cash burn is coming from Litigation expenses and a bit from Research and Development. Litigation in Delaware is on a contingency basis as such Enzo is not on the hook for billable hours. To my knowledge there are 6 suits left after 6 have settled.
When the company gets a 500 million dollar market cap ($10.63) they will qualify for those Institutions that can’t buy microcap stocks. A significant number of Institutions will look to be buyers and with only 47 million shares issued and Institutions already owning 50% and insiders owning 15% that leaves less than 17 million shares in the float.
Pressure Bio Sciences OTCQB: PBIO ( 5.95 )* Reversed 1 for 30 on June 5th ; Recently announced the signing of a new CFO Mr. Joseph L. Damasio, Jr. Mr. Damasio has over 20 years of finance and accounting experience most recently as Finance Director at Nelipak Packaging, a private equity backed medical packaging manufacturer with over $ 100 million in global annual sales. Before joining Nelipak, Mr. Damasio held financial positions at CP Bourg, IQEKC, and Kopin Corporation. Mr. Damasio was employed by Pressure BioSciences as both accounting manager (2007) and controller (2008) and finally as Vice President of Finance and Administration (2011).
The hiring of Mr. Damasio will allow the Company’s CEO Mr. Richard T Schumacher, who has been the company’s interim CFO for the past two years, and who has been a successful serial life sciences entrepreneur with three successful publicly traded companies to his credit, time to focus on critical operational issues in 2017. Some issues to be attended to include a pending up-list to NASADAQ and their stated goal to build a field sales team this year.
PBIO Develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, they have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders.
NEEDS IN MEDICINE: In the world of medicine our dramatically improved ability for early detection or to confirm and refine diagnosis ranging from over a hundred types of cancer to tuberculosis and a hundred other maladies and conditions is “bottlenecked” by 30 year old methods of preparing test samples. Collectively such diagnostic samples exceed a hundred million annually.
NEEDS IN RESEARCH: Globally there are over a half a million medical and pharmaceutical research scientists working in over eighty thousand laboratories who are hampered by the time consuming and outdated methods of preparing test samples.
NEEDS IN FORENSICS: Globally, in millions of cases, swift and sure exoneration of the innocent and / or justice for the guilty is often delayed or even denied because of the ponderous means of preparing and conducting DNA and other forensic testing.
PBIO is focused on solving the challenges of biological sample preparation, a crucial laboratory step performed globally by the biological life sciences research scientists. Sample preparation refers to a wide range of activities that precede most forms of scientific analysis. It is often complex, time-consuming and, in our opinion, one of the most error-prone steps of scientific research. Sample preparation is a ubiquitous laboratory undertaking – the requirements of which drive a large and growing worldwide market. PBIO has developed and patented a novel, enabling technology platform that can control the sample preparation process while improving both efficacy and quality. It is based on harnessing the unique properties of high hydrostatic pressure. This process, called pressure cycling technology, or PCT, uses alternating cycles of hydrostatic pressure between ambient (normal atmosphere) and ultra-high levels i.e., 35,000 pounds per square inch (“psi”) or greater to safely, conveniently and reproducibly control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant and microbial sources.
The PBIO pressure cycling technology uses proprietary and internally developed instrumentation that is capable of cycling pressure between ambient and ultra-high levels at controlled temperatures and specific time intervals, to rapidly and repeatedly control the interactions of bio-molecules, such as deoxyribonucleic acid (“DNA”), ribonucleic acid (“RNA”), proteins, lipids and small molecules. Their laboratory instrument, the Barocycler®, and their internally developed consumables product line, which include Pressure Used to Lyse Samples for Extraction (“PULSE”) tubes, and other processing tubes, and application specific kits such as consumable products and reagents, together make up their PCT Sample Preparation System (“PCT SPS”).
The PBIO pressure cycling technology takes a unique approach that has the potential for broad use in a number of established and emerging life sciences areas, which include:
- Biological sample preparation in potentially thousands of research laboratories worldwide working in human, animal, plant, and microbial diseases and disorders – including but not limited to sample extraction, homogenization, and digestion in genomic, proteomic, lipidomic, metabolomic and small molecule study areas;
- Pathogen inactivation (useful in vaccine development, infectious disease research, and more);
- Protein purification, and in the control of chemical reactions, particularly enzymatic (useful in drug design and development);
- and immunodiagnostics (useful in the development and detection of biomarkers).
INTELLECTUAL PROPERTY
PBIO has secured their technology through fourteen issued United States patents and ten issued foreign patents covering multiple applications of pressure cycling technology in the life sciences field. They also have additional patents pending. Research indicates that Pressure Bio Science, Inc. is the only company globally to have patents in this new science sector.
NightFood, Inc. (NGTF 0. 30)* has healthy night-time food specially formulated for nighttime snackers. The Company has an exclusive agreement with RFI, natural ingredient manufacturer and proprietor of Chocamine, a patented cocoa extract which helps with cravings and mood (calmness), and promotes feelings of satiety.
Americans keep gaining more weight. People have the tendency to grab for goodies at the end of the evening as they relax to enjoy some T.V. Eating and snacking too late at night is a contributing factor to gaining weight. Seventy percent of adults, ages 18-54, snack in the hour or two before bed. Chocamine delivers the health benefits of chocolate to the body (amino acids, minerals and polyphenols) without the added sugars, caffeine or fat.
People give in to the intense hunger cravings that leads to the consumption of sugary, salty or calorie dense foods to satisfy their appetite and cravings. Most of the snacks that people typically eat can impair sleep, causing a person to wake up feeling unrested. Night Food offers better-for-you alternatives to high-calorie and sleep disruptive junk foods.
The company product line currently includes snack bars in two flavors, either Cookies and Dreams or Midnight Chocolate Crunch. The company recently reported that it is looking into expanding the number of flavors in the Night Food bar line, and also manufacturing products in different snack formats, like ice cream or “bites”
Consumers spend over $50 billion/year on night-time snacks…over $1B every week. In general, snacking trends have shifted much healthier over the past several years, but industry research continues to show that the least healthy choices of the day occur as we get closer to bedtime. In fact, the four most popular nighttime snack categories, in order, are salty snacks (chips, pretzels, popcorn), ice cream, chocolate candy, and cookies,
Management believes that, just as there are energy versions of many popular foods (energy jerky, energy candy, energy waffles, energy gum, energy chips, energy bars), foods can also be formulated to be more nighttime appropriate and sleep-friendly.
We’ve seen it happen with low-carb, we’ve seen it happen with gluten-free. Can it happen with nighttime snacking as well?
Leo Motors (LEOM: $ 0. 11)* has patents for the electric battery industry which we will be writing about in upcoming weekly reports. They have developed a lithium battery that can operate vehicles in sub-zero climates. Their subsidiary LGM has developed battery technology supported by the Korean government to make it possible to use electric battery technology for fishing boats. They have a cartridge system which is a light-weight replacement method of swapping electric batteries.
Fishing has been harmed by the noise and oil leaks from internal combustion engines. LGM has solved that problem and besides eliminating the toxic problem, operating costs are reduced by 25%.
In addition they have a special patent for averting electric hazards and shocks. Leo developed the Internet of Things for e-boats which is networked and connected with an Android Operating System. Leo’s power supply system is CAN (Controller Area Network) based, which enables mobile diagnostics between mobile devices and boats using the Leo technology.
Leo is developing a battery swap system for Kalmado in Puerto Princesa, Philippines, a world famous tourist attraction, which is focused on green energy. They will be converting 100 boats as the environment is expected to become 100% free of the toxicity from internal combustion engines. Also, Leo has developed a battery swap system for Go-Karts to be used in malls in China, Korea and Myanmar. Leo Motors has a new carbon nanotube battery power pack that functions and supplies full power in extreme low temperatures such as below 49 degrees without the need for grid electricity.
Skinvisible ( SKVI: $ 0.027 )*: they have developed skin care products using its patented Invisicare polymer delivery systems and transdermal cannabis products from hemp-derived CBD, with its new developments to include cannabinoids from marijuana CBD and THC.
Rule 17B Attestations and Disclaimers
Princeton Research, Inc. has approximately 2,581,578 shares of AIVN both free and restricted and represents them for Investor relations. Princeton also has about 40,000 shares of TXGE. Princeton is paid $ 1,500 per month from RMS Medical Products. Princeton has bought 81,100 shares of RMS Medical Products. Princeton was paid $ 2,500 to write a report on Xinergy. Princeton has signed a contract with CBLI to be paid $ 2500 for July and August for investor relations. Princeton has been engaged by Target Energy. No contract is currently in place. Princeton was paid about 500,000 restricted shares of Leo Motors.
When there is no movement in penny stocks, even though there is none or very small losses, we will liquidate ( sold AIVN on stop ) even though we like the company, if money is needed for better opportunities.
We now believe REPR represents upside opportunity. The Target ADR trades at about $ 4.50 in U.S. vs 0.05 in Australia. Princeton owns 400,000 Australia shares and about 900 U.S. ADR’s.
Pursuant to the provisions of Rule 206 (4) of the Investment Advisers Act of 1940, readers should recognize that not all recommendations made in the future will be profitable or will equal the performance of any recommendations referred to in this e-mail issue. Princeton may buy or sell its free-trading shares in companies it represents at any time.
CONTACT
Please Direct All Inquiries To:
Mike King
(702) 650-3000
Where to invest NOW